Free Trial

MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis

MoonLake Immunotherapeutics logo
$8.43 +0.97 (+13.00%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$8.72 +0.29 (+3.44%)
As of 04:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)

Advanced

Key Stats

Today's Range
$7.50
$8.50
50-Day Range
$6.24
$61.99
52-Week Range
$5.95
$62.75
Volume
15.52 million shs
Average Volume
8.51 million shs
Market Capitalization
$541.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.00
Consensus Rating
Hold

Company Overview

MoonLake Immunotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

MLTX MarketRank™: 

MoonLake Immunotherapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 436th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MoonLake Immunotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.07, and is based on 3 buy ratings, 9 hold ratings, and 2 sell ratings.

  • Upside Potential

    MoonLake Immunotherapeutics has a consensus price target of $37.00, representing about 338.9% upside from its current price of $8.43.

  • Amount of Analyst Coverage

    MoonLake Immunotherapeutics has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about MoonLake Immunotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($1.79) to ($2.65) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MoonLake Immunotherapeutics is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MoonLake Immunotherapeutics is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MoonLake Immunotherapeutics has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about MoonLake Immunotherapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    8.98% of the float of MoonLake Immunotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    MoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

    Short interest in MoonLake Immunotherapeutics has recently decreased by 4.44%, indicating that investor sentiment is improving.
  • Dividend Yield

    MoonLake Immunotherapeutics does not currently pay a dividend.

  • Dividend Growth

    MoonLake Immunotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.98% of the float of MoonLake Immunotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    MoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

    Short interest in MoonLake Immunotherapeutics has recently decreased by 4.44%, indicating that investor sentiment is improving.
  • News Sentiment

    MoonLake Immunotherapeutics has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 110 news articles for MoonLake Immunotherapeutics this week, compared to 7 articles on an average week.
  • Search Interest

    77 people have searched for MLTX on MarketBeat in the last 30 days. This is an increase of 7,600% compared to the previous 30 days.
  • MarketBeat Follows

    17 people have added MoonLake Immunotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 750% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MoonLake Immunotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $46,863,385.00 in company stock.

  • Percentage Held by Insiders

    12.02% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MoonLake Immunotherapeutics' insider trading history.
Receive MLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MLTX Stock News Headlines

Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do…tc pixel
Research Analysts Set Expectations for MLTX Q1 Earnings
See More Headlines

MLTX Stock Analysis - Frequently Asked Questions

MoonLake Immunotherapeutics' stock was trading at $54.15 at the beginning of 2025. Since then, MLTX shares have decreased by 84.4% and is now trading at $8.43.

MoonLake Immunotherapeutics (NASDAQ:MLTX) issued its quarterly earnings data on Tuesday, August, 5th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by $0.14.

Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MoonLake Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Disc Medicine (IRON), e.l.f. Beauty (ELF), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/05/2025
Today
10/05/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MLTX
CIK
1821586
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

High Price Target
$100.00
Low Price Target
$7.00
Potential Upside/Downside
+338.9%
Consensus Rating
Hold
Rating Score (0-4)
2.07
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$118.94 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-40.98%
Return on Assets
-35.81%

Debt

Debt-to-Equity Ratio
0.21
Current Ratio
16.65
Quick Ratio
16.65

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.09 per share
Price / Book
1.19

Miscellaneous

Outstanding Shares
64,230,000
Free Float
56,510,000
Market Cap
$541.46 million
Optionable
Optionable
Beta
1.10
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:MLTX) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners